A forum for researchers, students and applicants in the field of cyclodextrin technology
2-hydroxypropyl-ß-cyclodextrin (kleptose) is used for the treatment of Niemann–Pick disease. Kleptose crosses the blood–brain barrier poorly, in part because of
To establish a method for the orthogonal chemical functionalization of β-cyclodextrin (β-CD)-based polyrotaxane (PRX), unmodified and monoazidated β-CDs (N3-β-CDs) were
Businesswire published: Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase
A major side effect of using high doses of HPβCD to treat Niemann Pick type C (NPC1) disease is sensorineural
The acoustic startle reflex (ASR) amplitude can be enhanced or suppressed by noise-induced hearing loss or age-related hearing loss; however,
On January 24-25, 2022, the FDA and Duke-Margolis Center for Health Policy will host a virtual publicworkshop on endpoint considerations
Dec 9, 2021 – Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first
The complexity and organization of the central nervous system (CNS) is widely modulated by the presence of the blood–brain barrier
On July 27, the Cyclo Therapeutics, a clinical stage biotechnology firm dedicated to developing life-changing medicines through science and innovation
Recent reviews emphasized the role of membrane lipids in the infectivity mechanism of SARS-COV-2. Cholesterol-rich parts of cell membranes serve
